Search Results for “diabetes” – Page 8 – media

Health2Sync raises $6M to expand its diabetes tracking and management service in Asia

Health2Sync, a Taiwan-headquartered company that offers a diabetes tracking service, has closed a $6 million Series B round aimed at expanding its business in Japan and other markets in Asia.
- Source: drugdu
- 493
- December 11, 2017
diabetes diabetes tracking service Health2Sync Series
Weight Loss Really Can Reverse Diabetes, New Study Finds

in a paper published in the Lancet, researchers in the UK describe a landmark study in which people with diabetes went into remission—just by losing weight.
- Source: in a paper published in the Lancet, researchers in the UK describe a landmark study in which people with diabetes went into remission—just by losing weight.
- 542
- December 7, 2017
diabetes weight loss
Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for OZEMPIC® (semaglutide) injection 0.5 mg or 1 mg, a once-weekly glucagon-like peptide (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.1 OZEMPIC® is administered once weekly, on the same day each week, and can be taken any time of the day, with or without meals.
- Source: medicalxpress
- 574
- December 6, 2017
diabetes FDA Novo Nordisk OZEMPIC®
Jardiance is the first and only oral type 2 diabetes medicine approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

New data presented today showed that Jardiance® reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease.
- Source: finance.yahoo
- 607
- November 17, 2017
cardiovascular diabetes Jardiance® peripheral artery disease
Study reveals how a very low calorie diet can reverse type 2 diabetes

In a new study, a Yale-led research team uncovers how a very low calorie diet can rapidly reverse type 2 diabetes in animal models. If confirmed in people, the insight provides potential new drug targets for treating this common chronic disease, said the researchers.
- Source: Medicalxpress
- 538
- November 14, 2017
calorie chronic diabetes Researches
Do Children’s Antibiotics Lead to Type 1 Diabetes or Celiac Disease?

In a recent study, researchers investigated whether there is a link between children’s antibiotics and the rise of autoimmune diseases such as type 1 diabetes and celiac disease.
- Source: medicalnewsbulletin
- 624
- November 13, 2017
antibiotics autoimmune celiac diabetes Researches
Just two sugary drinks per week may raise type 2 diabetes risk

The World Health Organization (WHO) report that at least 19 million yearly deaths are from cardiometabolic disorders – an umbrella term for cardiovascular disease and conditions such as metabolic syndrome and type 2 diabetes.
- Source: medicalnewstoday
- 590
- November 7, 2017
cardiometabolic diabetes Market Views WHO
One Drop Integrates With Fitbit to Deliver Enhanced Diabetes Management Data Insights

One Drop, a leading diabetes care management platform announced they are partnering with Fitbit to help people better manage their Diabetes. By working together, Fitbit and One Drop can help make it easier for people to see how physical activity can impact blood glucose levels and make more informed care management decisions. In addition, One Drop will build an App for Fitbit Ionic, bringing One Drop data to the wrist.
- Source: hitconsultant
- 504
- November 1, 2017
blood glucose levels diabetes Market Views SDK
Diabetes–New compounds may lower blood sugar but prevent weight gain

Researchers are one step closer to a new drug that could lower blood glucose levels in patients with insulin resistance, but without the potentially harmful side effects.
- Source: medicalnewstoday
- 732
- October 26, 2017
blood glucose diabetes insulin Researches resistance
FDA Approves Once-Weekly Bydureon BCise (exenatide) for Patients with Type-2 Diabetes

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon® BCise™ (exenatide extended-release) injectable suspension, a new formulation of Bydureon (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise, to improve glycemic control.
- Source: AstraZeneca
- 460
- October 25, 2017
Bydureon diabetes New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.